Subsidy Information and Financing Scheme MSHLIdelalisib Tablet 150 mg Treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic... See all × MSHLIdelalisib Tablet 150 mg Treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.
Post Marketing Information DHCPL 13/04/2016 Decreased overall survival and increased risk of serious infections in patients receiving Zydelig® (idelalisib) for first line treatment of Chronic Lymphocytic Leukemia (CLL) and relapsed Indolent Non-Hodgkin Lymphoma (iNHL)